5.40
前日終値:
$5.37
開ける:
$5.17
24時間の取引高:
679.62K
Relative Volume:
0.17
時価総額:
$7.95M
収益:
-
当期純損益:
$-5.73M
株価収益率:
-0.8244
EPS:
-6.55
ネットキャッシュフロー:
$-4.13M
1週間 パフォーマンス:
+31.01%
1か月 パフォーマンス:
-13.90%
6か月 パフォーマンス:
+32.60%
1年 パフォーマンス:
+0.00%
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
名前
Dogwood Therapeutics Inc
セクター
電話
(866) 620-8655
住所
44 MILTON AVENUE, ALPHARETTA
DWTX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DWTX
Dogwood Therapeutics Inc
|
5.45 | 7.95M | 0 | -5.73M | -4.13M | -6.55 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.40 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.35 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.91 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.34 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc (DWTX) 最新ニュース
Dogwood Therapeutics Inc (NASDAQ: DWTX) Has Been Trading Down. What Are The Prospects For The Future? - Stocksregister
You might want to take a look at Dogwood Therapeutics Inc (DWTX) now - Sete News
You Should Read This Analysis Before Investing in Dogwood Therapeutics Inc (NASDAQ:DWTX) - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dogwood Therapeutics (DWTX) Begins Phase 2b Trial for Halneuron - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance with Equit - GuruFocus
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com South Africa
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance - marketscreener.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest - Stock Titan
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance
Dogwood Therapeutics regains compliance with Nasdaq - MSN
Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com
Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire
Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Dogwood Therapeutics announces pricing of $4.8 million offering - MSN
Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge -March 13, 2025 at 09:40 am EDT - Marketscreener.com
Dogwood Therapeutics secures $4.8 million in direct offering By Investing.com - Investing.com Australia
Dogwood Therapeutics secures $4.8 million in direct offering - Investing.com
Dogwood Therapeutics Secures $4.8 Million in Direct Offering to Advance Halneuron® Phase 2b Trial and Fund Operations Through Q1 2026 - Nasdaq
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 - GlobeNewswire
Dogwood Secures Critical Funding for Revolutionary Pain Treatment: What's Next for Halneuron? - StockTitan
Dogwood Therapeutics Announces Pricing Of $4.8 Million Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules - marketscreener.com
Dogwood Therapeutics clears debt with equity swa By Investing.com - Investing.com Australia
Dogwood Therapeutics converts existing debt to equity -March 12, 2025 at 10:34 am EDT - Marketscreener.com
Dogwood Therapeutics Strengthens Balance Sheet with Debt Conversion - TipRanks
Dogwood Therapeutics clears debt with equity swa - Investing.com
Dogwood Therapeutics Announces Debt-to-Equity Exchange with CK Life Sciences, Strengthening Financial Position for Clinical Trials - Nasdaq
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward - Financial Post
Dogwood Therapeutics, Inc. Announces Conversion of Existing - GlobeNewswire
Major Breakthrough: Dogwood Therapeutics Wipes Out All Debt as Top Investor Backs Pain Drug Future - StockTitan
Dogwood Therapeutics (DWTX) to Release Earnings on Thursday - Defense World
Dogwood Therapeutics Inc expected to post a loss of $1.41 a shareEarnings Preview - TradingView
DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth - MSN
Closing Figures Unveiled: Dogwood Therapeutics Inc (DWTX) Gain 13.53, Closes at 14.18 - The Dwinnex
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Stock market news: Planet Image International +132.83%, Akero Therapeutics +94.04% among top gainers during mid day trading - Business Upturn
Dogwood Therapeutics Inc (DWTX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):